Tradestie Institutional Equity Comparison Engine

ANRO vs VIVS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANRO Overall Edge

ANRO Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ANRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus VIVS at N/M Forward P/E and -10117.0% operating margin (-51.4% YoY). In options structure, ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ANRO N/M vs VIVS N/M Fwd P/E
Growth & Margin Winner ANRO
Op Margin 0.0% vs -10117.0% ยท YoY +0.0% vs -51.4%
Momentum & Technical Winner ANRO
1Y +79.7% vs -87.0% ยท 52W Pos 56% vs 5%
Options & Structure Winner ANRO
BREAKDOWN (8th %ile IV) vs BREAKDOWN (N/A IV)
ANRO NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$26.51
+2.32% 1D
Market Cap $1.0B
1M Return +13.68%
1Y Return +79.73%
Forward P/E N/M
Unified AI Score
34.1 / 100 SELL
Tech 15.0 Fund 38.0 Flow 65.0 Mom 40.0
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
1M Return +64.69%
1Y Return -86.99%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ANRO +79.73% VIVS -86.99% Spread: +166.72 pp (ANRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ANRO TTM Op. Margin: 0.0% VIVS TTM Op. Margin: -10117.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs VIVS. Trailing 12-month operating profitability (ANRO 0.0% vs VIVS -10117.0%) and valuation multiples (ANRO N/M vs VIVS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ANRO (6) vs VIVS (1)
Institutional Metric ANRO VIVS Criterion Row Winner
Market Capitalization Scale $1.0B $2.4M Larger Scale ANRO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -51.4% Higher Growth ANRO
Operating Margin (TTM) Profitability 0.0% -10117.0% Higher Margin ANRO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -46.7% -343.1% Higher ROE ANRO
52-Week Range Position Momentum 56% ($13โ€“$37) 5% ($0โ€“$3) Stronger Trend ANRO
Beta / 30D Volatility Risk Regime 1.95ฮฒ ยท 91% Vol 0.83ฮฒ ยท 480% Vol Lower Realized Risk ANRO
Unified Institutional Score Composite Signal 34.1 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite VIVS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ANRO vs VIVS Buy Guide
ANRO BREAKDOWN
60d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live ANRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VIVS BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VIVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ANRO nor VIVS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.